Agomab Doses First Patient in Ontunisertib Crohn’s Disease Phase 2b Trial: A Pivotal Step
Ontunisertib Crohn’s disease Phase 2b trial opens: first patient dosed in NOV-ERA, about 320 adults. The drug is unapproved and efficacy is unproven.
Ontunisertib Crohn’s disease Phase 2b trial opens: first patient dosed in NOV-ERA, about 320 adults. The drug is unapproved and efficacy is unproven.